One of the first medicinal cannabis products available in Australia.

The capsules are used to treat a variety of medical conditions

’s ( ) Australian distribution partner has successfully imported the first shipment of medicinal products from MMJ’s Swiss-subsidiary, Satipharm AG.

The imported products include two strengths of cannabidiol (CBD) capsules, which are used in the treatment of a variety of medical conditions.

Satipharm’s Gelpell CBD capsules will be used as approved by prescribing physicians under Australian Federal and State laws and regulations.

The Gelpell CBD capsules are one of the first medicinal cannabis products available to approved prescribers in Australia.

Harvest One Cannabis (CVE:HVST) (60% owned by MMJ) owns a cannabis facility in British Columbia, targeting the production of 8,500 kilograms of dried cannabis buds per annum by the end of 2017.

Following a recent agreement to secure a land package located adjacent to the existing facility, Harvest One is aiming to drive production capacity to 50,000 kilograms per annum by 2020.

The Cannabis Act- a bill to legalise the growth, sale, and consumption of recreational marijuana in Canada, is expected to become a law by July 2018.

Cannabis is already big business in Canada. The drug was approved for medicinal use 20 years ago, and almost 30% of young adults say they use it recreationally.

MMJ’s share price has increased circa 82% since the start of 2017, last trading at $0.40.